Associated Genetic Biomarkers
Associated Diseases
Associated Pathways

Overview

Location [1]
12p12.1
Pathway
MAP kinase signaling
Protein [2]
GTPase KRas, N-terminally processed
Synonyms [1]
KRAS1, K-RAS4A, RASK2, C-K-RAS, KRAS2, K-RAS2A, CFC2, NS, RALD, KI-RAS, K-RAS4B, c-Ki-ras2, K-RAS2B, NS3

KRAS (Kirsten rat sarcoma viral oncogene homolog) encodes for the GTPase KRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. KRAS is implicated in the pathogenesis of several cancers.

KRAS is altered in 15.66% of all cancers with colorectal adenocarcinoma, non-small cell lung carcinoma, pancreatic exocrine neoplasm, uterine corpus neoplasm, and ovarian neoplasm having the greatest prevalence of alterations [3].

KRAS GENIE Cases - Top Diseases

The most common alterations in KRAS are KRAS Mutation (20.55%), KRAS Mutation (germline) (20.55%), KRAS Mutation (somatic) (20.55%), KRAS Codon 12 Missense (15.92%), and KRAS G12D (5.57%) [3].

KRAS GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of KRAS in Diseases

Non-Small Cell Lung Carcinoma +

Malignant Solid Tumor +

Colorectal Carcinoma +

Acute Myeloid Leukemia +

Pancreatic Carcinoma +

Colorectal Adenocarcinoma +

Myelodysplastic Syndromes +

Pancreatic Ductal Adenocarcinoma +

Non-Hodgkin Lymphoma +

Chronic Myelomonocytic Leukemia +

Melanoma +

Breast Carcinoma +

Multiple Myeloma +

Acute Lymphoblastic Leukemia +

Squamous Cell Lung Carcinoma +

Glioma +

Ovarian Carcinoma +

Cancer +

Head And Neck Squamous Cell Carcinoma +

Neurofibromatosis Type 1 +

Colon Carcinoma +

Lung Adenocarcinoma +

Esophageal Carcinoma +

Bladder Carcinoma +

Small Cell Lung Carcinoma +

Diffuse Large B-Cell Lymphoma +

Renal Cell Carcinoma +

Neuroblastoma +

Rectal Carcinoma +

Endometrial Carcinoma +

Cholangiocarcinoma +

Lung Carcinoma +

Germ Cell Tumor +

Adenocarcinoma Of The Gastroesophageal Junction +

Malignant Ovarian Epithelial Tumor +

Gastric Carcinoma +

Gastric Adenocarcinoma +

Urothelial Carcinoma +

Thyroid Gland Carcinoma +

Malignant Peripheral Nerve Sheath Tumor +

Papillary Renal Cell Carcinoma +

Poorly Differentiated Thyroid Gland Carcinoma +

Thyroid Gland Adenocarcinoma +

Mantle Cell Lymphoma +

Anaplastic Astrocytoma +

Rhabdomyosarcoma +

Histiocytic And Dendritic Cell Neoplasm +

Thyroid Gland Follicular Carcinoma +

Thyroid Gland Papillary Carcinoma +

Lymphoma +

Sarcoma +

Chronic Myeloid Leukemia +

Head And Neck Carcinoma +

Soft Tissue Sarcoma +

Glioblastoma +

Prostate Carcinoma +

Gastrointestinal Stromal Tumor +

Hepatocellular Carcinoma +

Clear Cell Renal Cell Carcinoma +

Double-Hit Lymphoma +

Juvenile Myelomonocytic Leukemia +

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +

Peripheral T-Cell Lymphoma +

Peritoneal Mesothelioma +

Pleural Mesothelioma +

Refractory Anemia With Excess Blasts +

Refractory Anemia With Excess Blasts-2 +

Rhabdoid Tumor +

Schwannoma +

Secondary Acute Myeloid Leukemia +

Therapy-Related Acute Myeloid Leukemia +

Thymic Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.